Table 3.
Best confirmed hematological response after completion of induction therapy and three months after the first ASCT
| Parameter | VAD n = 95 |
VMP n = 93 |
BPV n = 169 |
VD n = 33 |
PAD n = 29 |
VCD n = 70 |
|---|---|---|---|---|---|---|
| Response after induction | ||||||
| sCR, n (%) | 1 (1) | 7 (8) | 10 (6) | 0 | 1 (3) | 1 (1) |
| CR, n (%) | 1 (1) | 3 (3) | 4 (2) | 1 (3) | 0 | 1 (1) |
| nCR, n (%) | 0 | 9 (10) | 12 (7) | 3 (9) | 1 (3) | 2 (3) |
| VGPR, n (%) | 11 (12) | 10 (11) | 40 (24) | 7 (21) | 10 (34) | 16 (23) |
| PR, n (%) | 50 (53) | 43 (46) | 75 (44) | 17 (51) | 13 (45) | 39 (56) |
| ≥ CR, n (%) | 2 (2) | 10 (11) | 14 (8) | 1 (3) | 1 (3) | 2 (3) |
| ≥ VGPR, n (%) | 13 (14) | 29 (31) | 66 (39) | 11 (33) | 12 (41) | 20 (29) |
| ORR, n (%) | 64 (66) | 72 (77) | 141(83) | 28 (85) | 25 (86) | 59 (84) |
| Response after first ASCT | ||||||
| sCR, n (%) | 5 (5) | 12 (13) | 35 (21) | 5 (15) | 5 (17) | 5 (7) |
| CR, n (%) | 7 (7) | 7 (8) | 13 (8) | 2 (6) | 2 (7) | 4 (6) |
| nCR, n (%) | 5 (5) | 17 (18) | 33 (20) | 4 (12) | 11 (38) | 13 (19) |
| VGPR, n (%) | 26 (27) | 23 (25) | 56 (33) | 13 (39) | 5 (17) | 33 (47) |
| PR, n (%) | 48 (51) | 32 (34) | 29 (17) | 8 (24) | 5 (17) | 11 (16) |
| ≥ CR, n (%) | 12 (13) | 19 (20) | 48 (28) | 7 (21) | 7 (24) | 9 (13) |
| ≥ VGPR, n (%) | 43 (45) | 59 (63) | 137 (81) | 24 (73) | 23 (79) | 55 (79) |
| ORR, n (%) | 91 (96) | 91 (98) | 166 (98) | 32 (97) | 28 (97) | 66 (94) |
| Median PFS (months) | 35 | 36 | 47 | 31 | 39 | 54 |
| Median OS (months) | 78 | 72 | 80 | 64 | 74 | nra |
Italic values represent cumulative results
sCR: stringent complete response; CR: complete response; nCR: near-complete response; VGPR: very good partial response; PR: partial response; ORR: overall response rate; nr: not reached
aMedian observation time in the VCD group is only 21 months